Friday, 25 September 2026European Markets

ATENOR Stock 19.81% Up On Tuesday

Loading stream...

(VIANEWS) - The Market ended the session with ATENOR (ATEB.BR) rising 19.81% to €12.40 on Tuesday, following the last session's upward trend. BEL 20 jumped 1.75% to €3,540.94, following the last session's downward trend on what was an all-around positive trend exchanging session today.

About ATENOR

Atenor SA, a real estate development company, invests in large-scale real estate projects in Belgium, Luxembourg, the Netherlands, France, Germany, Portugal, Poland, Hungary, the United Kingdom, and Romania. The company develops real estate projects, such as offices and residential buildings. Atenor SA was founded in 1910 and is headquartered in La Hulpe, Belgium.

Earnings Per Share

As for profitability, ATENOR has a trailing twelve months EPS of €-9.45.

Volume

Today's last reported volume for ATENOR is 15165 which is 163.69% above its average volume of 5751.

Volatility

ATENOR's last week, last month's, and last quarter's current intraday variation average was a positive 2.25%, a negative 2.68%, and a positive 3.23%.

ATENOR's highest amplitude of average volatility was 5.14% (last week), 5.19% (last month), and 3.23% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ATENOR's stock is considered to be oversold (<=20).

More news about ATENOR (ATEB.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Scale Up Through Partnerships and Funding, But Data Readiness Lags Ambition
A wave of vertical AI-agent startups (Swarm, Veridox, Avallon AI, DA2, F2, Earthian, Meanwhile, Covecta, Penguin AI, Maisa AI) is being funded and profiled just as major infrastructure players — Microsoft/Mistral, Siemens/NVIDIA, and Manulife/Microsoft — cement enterprise AI governance and compute partnerships. Yet a Google Cloud report shows AI agents still lack access to the majority of company data (only 45% on average), and insider selling at incumbent C3.ai signals investor caution even as adoption intent (100% planned agentic AI use within two years) races ahead of actual data infrastructure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com